NULOJIX
Biological
E.R. Squibb & Sons, L.L.C.
Total Payments
$16.9M
Transactions
1,118
Doctors
286
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4,904 | 47 | 31 |
| 2023 | $46.00 | 1 | 1 |
| 2022 | $5,538 | 4 | 3 |
| 2021 | $687.50 | 1 | 1 |
| 2020 | $51,936 | 138 | 89 |
| 2019 | $3.0M | 426 | 155 |
| 2018 | $5.2M | 213 | 27 |
| 2017 | $8.6M | 288 | 58 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.6M | 432 | 98.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $88,275 | 22 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $81,800 | 36 | 0.5% |
| Consulting Fee | $45,090 | 26 | 0.3% |
| Travel and Lodging | $26,312 | 82 | 0.2% |
| Education | $25,238 | 23 | 0.1% |
| Food and Beverage | $19,211 | 497 | 0.1% |
Payments by Type
Research
$16.6M
432 transactions
General
$285,925
686 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Transplant Solid Organ Transplant Kidney | E.R. Squibb & Sons, L.L.C. | $3.8M | 0 |
| Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix Belatacept Based Immunosuppression | E.R. Squibb & Sons, L.L.C. | $2.7M | 0 |
| PK comparability study to support Process E manufacturing | E.R. Squibb & Sons, L.L.C. | $1.7M | 0 |
| Evaluating Nulojix Long Term Safety in Transplant | E.R. Squibb & Sons, L.L.C. | $1.6M | 0 |
| Phase IIIB CNI to bela Switch Study | E.R. Squibb & Sons, L.L.C. | $1.3M | 0 |
| Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction CNI free Nulojix Belatacept Based Immunosuppression | E.R. Squibb & Sons, L.L.C. | $1.0M | 0 |
| Transplant Solid Organ Transplant-Kidney | E.R. Squibb & Sons, L.L.C. | $466,022 | 0 |
| Evaluating Nulojix Long-Term Safety in Transplant | E.R. Squibb & Sons, L.L.C. | $458,120 | 0 |
| Using Bela to Reduce Proteinuria in Rnl Tran Recipients with B7 1 Positive Biopsy Specimens a Pilot Interventional Multi-Center sty | E.R. Squibb & Sons, L.L.C. | $426,199 | 0 |
| Ran Con of EBV Kdy Tran Rec of Liv or Stan Crit Dnrs at 3 M Pst Trans frm Tacro to Bela w MPA or Bela w low d Tacro 50 prcnt d red comp | E.R. Squibb & Sons, L.L.C. | $412,877 | 0 |
| Phase IIB LCM Regimen Optimization Thymo | E.R. Squibb & Sons, L.L.C. | $366,004 | 0 |
| Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix Belatacept-Based Immunosuppression | E.R. Squibb & Sons, L.L.C. | $334,438 | 0 |
| A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes | E.R. Squibb & Sons, L.L.C. | $275,797 | 0 |
| Bela Therapy for the Failing Renal Allograft | E.R. Squibb & Sons, L.L.C. | $228,435 | 0 |
| Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix Belatacept-Based Immunosuppression | E.R. Squibb & Sons, L.L.C. | $224,682 | 0 |
| Ran clin trl of eff and saf on bela comp to tacrolimus in set of rab antithymocyte glob induct and rpd strd disc in dec dnr rnl trans recip | E.R. Squibb & Sons, L.L.C. | $219,523 | 0 |
| Using Bela to Reduce Proteinuria in Rnl Tran Recipients with B7 1 Positive Biopsy Specimens a Pilot Interventional Multi Center sty | E.R. Squibb & Sons, L.L.C. | $198,803 | 0 |
| Prosp rand trial of Belatacept switch in Renal Transplant Recipients with Delayed Graft Function | E.R. Squibb & Sons, L.L.C. | $156,593 | 0 |
| US REGISTRY OF BELATACEPT TREATED PATIENTS FOR THE ASSESSMENT OF PTLD CNS PTLD AND PML | E.R. Squibb & Sons, L.L.C. | $114,219 | 0 |
| Belatacept Mech CostimPrimate RenalTransplant Non BMS Spons | E.R. Squibb & Sons, L.L.C. | $106,000 | 0 |
Top Doctors Receiving Payments for NULOJIX — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Riverside, RI | $100.91 | 1 |
| , MD | Surgery | Providence, RI | $100.91 | 1 |
| , MD | Nephrology | Riverside, RI | $100.91 | 1 |
| , M.D | Nephrology | Oakland, CA | $99.10 | 1 |
| , M.D | Pediatrics | Atascadero, CA | $99.10 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Sugar Land, TX | $99.10 | 1 |
| , M.D | Internal Medicine | San Francisco, CA | $99.10 | 1 |
| , MD | Nephrology | Oakland, CA | $99.10 | 1 |
| , MD | Surgery | San Francisco, CA | $99.10 | 1 |
| Jason Law | Nephrology | Concord, CA | $99.10 | 1 |
| Carol Traynor | Student in an Organized Health Care Education/Training Program | Durham, NC | $99.07 | 1 |
| , M.D | Nephrology | Buffalo, NY | $99.07 | 1 |
| , MD | Nephrology | Baltimore, MD | $99.07 | 1 |
| , MD | Internal Medicine | Loma Linda, CA | $99.07 | 1 |
| , M.D | Nephrology | Flossmoor, IL | $99.07 | 1 |
| , MD | Internal Medicine | Meridian, MS | $99.07 | 1 |
| , M.D | Internal Medicine | Tampa, FL | $98.76 | 1 |
| , MD | Nephrology | Fairfax, VA | $97.73 | 1 |
| , M.D | Internal Medicine | Arlington, VA | $97.73 | 1 |
| , M.D | Nephrology | Fairfax, VA | $97.73 | 1 |
| , M.D | Surgery | Chester, PA | $97.08 | 5 |
| , M.D | Internal Medicine | Kansas City, MO | $96.49 | 5 |
| , MD | Nephrology | Cleveland, OH | $94.61 | 1 |
| , MD | Urology | Cleveland, OH | $94.61 | 1 |
| , MD | Nephrology | Cleveland, OH | $94.61 | 1 |
Ad
Manufacturing Companies
- E.R. Squibb & Sons, L.L.C. $16.9M
Product Information
- Type Biological
- Total Payments $16.9M
- Total Doctors 286
- Transactions 1,118
About NULOJIX
NULOJIX is a biological associated with $16.9M in payments to 286 healthcare providers, recorded across 1,118 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2017 to 2024. In 2024, $4,904 was paid across 47 transactions to 31 doctors.
The most common payment nature for NULOJIX is "Unspecified" ($16.6M, 98.3% of total).
NULOJIX is associated with 20 research studies, including "Transplant Solid Organ Transplant Kidney" ($3.8M).